Line of treatment for stroke according to guidelines
Reading File
Stroke management is a broad clinical topic. Let me search the medical library and recent guidelines in parallel.
Searching sources...
Finding Sources
Searching PubMed
"ischemic stroke"[MeSH Terms] AND "treatment guideline"
Searching the Web
AHA ASA 2024 2025 ischemic stroke treatment guidelines line of treatment
Now let me read the textbook content on stroke and also extract the NIH StatPearls page for 2026 guidelines detail:
Reading File
Reading Web Page
https://www.ncbi.nlm.nih.gov/books/NBK499997
Searching PubMed
"ischemic stroke" AND "management" AND "guideline"
The 2026 AHA/ASA guideline is now published. Let me get the abstract and also read more of the textbook for hemorrhagic stroke and secondary prevention:
Reading Article
PMID: 41582814
Reading File
I now have comprehensive material from the textbook (Rosen's Emergency Medicine) and the 2026 AHA/ASA guideline. Let me compile the full answer.
Lines of Treatment for Stroke - 2026 AHA/ASA Guidelines
The 2026 AHA/ASA Guideline for the Early Management of Acute Ischemic Stroke (PMID 41582814) replaced the 2018/2019 guidelines. It is the current reference standard.
Type Classification First
Stroke is broadly divided into:
- Ischemic stroke (~85%) - thrombotic, embolic, lacunar
- Hemorrhagic stroke (~15%) - intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH)
Treatment is entirely different between the two types.
ISCHEMIC STROKE
Phase 1 - Prehospital & Emergency Stabilization
- Activate stroke code / stroke team immediately
- Airway, Breathing, Circulation (ABC) - O2 only if SpO2 <94%
- IV access and rapid labs (CBC, PT/INR, aPTT, glucose, metabolic panel)
- Urgent non-contrast CT head to exclude hemorrhage before any thrombolysis
- Target door-to-needle time: <60 minutes
- BP management: Do NOT aggressively lower BP unless >185/110 mmHg AND thrombolysis is being considered (target <185/110 pre-tPA)
- Blood glucose: Treat if <60 mg/dL (IV dextrose) or persistently >180 mg/dL (target 140-180 mg/dL)
Phase 2 - Acute Reperfusion (First-Line Interventions)
1. IV Thrombolysis (IVT) - First-Line Reperfusion
Alteplase (tPA) - 0.9 mg/kg IV (max 90 mg), 10% as bolus over 1 min, remainder over 60 min
| Time Window | Recommendation |
|---|---|
| 0-3 hours | Strongly recommended (Class I, Level A) for eligible patients |
| 3-4.5 hours | Recommended for most eligible patients; some additional exclusions apply |
| 4.5-9 hours | Reasonable if MRI shows FLAIR-diffusion mismatch or perfusion imaging shows salvageable penumbra |
| Wake-up stroke / unknown onset | IVT reasonable with MRI-guided selection (FLAIR-DWI mismatch) |
Tenecteplase (TNK) - 0.25 mg/kg IV (max 25 mg), single bolus
- 2026 guidelines now recommend either alteplase or tenecteplase within the 4.5-hour window, regardless of NIHSS score, without need for advanced imaging
- TNK preferred by many centers due to simpler single-bolus dosing
Mild non-disabling stroke: IVT is NOT recommended; use dual antiplatelet therapy instead.
2. Mechanical Endovascular Thrombectomy (EVT) - First-Line for Large Vessel Occlusion (LVO)
- Proceed with EVT regardless of tPA - do not wait to observe tPA response
- Window: Within 6 hours of symptom onset - strongest evidence (Class I)
- 6-24 hours: EVT reasonable in selected patients with salvageable penumbra on perfusion imaging (DAWN/DEFUSE-3 criteria)
- Target vessel: ICA, M1 MCA, basilar artery, and select M2 occlusions
Key EVT criteria:
- Pre-stroke mRS 0-1
- Causative occlusion of ICA or proximal MCA (M1)
- Age ≥18
- NIHSS ≥6
- ASPECTS ≥6 on CT
- Treatment initiation within 6-24 hours
Phase 3 - Early In-Hospital Management
| Parameter | Target / Action |
|---|---|
| BP after tPA | <180/105 mmHg for 24 hours post-thrombolysis |
| BP without tPA | Permissive hypertension unless >220/120 mmHg; lower gradually if needed |
| Blood glucose | 140-180 mg/dL; treat hypoglycemia aggressively |
| Temperature | Treat fever (>38°C) with antipyretics |
| Cardiac monitoring | Continuous for 24 hours (detect AF); initial troponin |
| Dysphagia screening | Before any oral intake |
| DVT prophylaxis | Compression stockings; LMWH when safe to initiate |
| Early mobilization | After 24-48 hours in stable patients |
Phase 4 - Antiplatelet Therapy (Acute & Secondary Prevention)
Cardioembolic stroke (AF-related):
- Anticoagulation (NOT antiplatelet) - warfarin, apixaban, rivaroxaban, dabigatran
- Timing: typically 4-14 days post-stroke depending on stroke size
Non-cardioembolic (atherosclerotic, lacunar):
| Scenario | Regimen |
|---|---|
| Mild-moderate AIS (NIHSS ≤3, non-disabling) | Dual antiplatelet (aspirin + clopidogrel) for 21 days, then monotherapy |
| Aspirin alone | 160-325 mg within 24-48 hours; long-term 75-100 mg/day |
| Clopidogrel | Alternative if aspirin intolerant |
| TIA or minor stroke | Aspirin + clopidogrel x 21 days (Class I, Level A - based on POINT/CHANCE trials) |
Phase 5 - Secondary Prevention (Long-term)
| Risk Factor | Treatment |
|---|---|
| AF | Oral anticoagulation (DOAC preferred over warfarin) |
| Hypertension | ACE inhibitor ± thiazide diuretic; target <130/80 mmHg |
| Dyslipidemia | High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) |
| Diabetes | Glycemic control; SGLT-2 inhibitors or GLP-1 agonists for cardiometabolic benefit |
| Carotid stenosis (>70%) | Carotid endarterectomy (CEA) or stenting within 2 weeks |
| PFO + cryptogenic stroke | PFO closure in patients <60 years (Class IIa) |
| Smoking | Cessation counseling |
| Lifestyle | Diet, exercise, weight reduction |
HEMORRHAGIC STROKE
Intracerebral Hemorrhage (ICH)
- Stop any anticoagulants immediately - reversal agents:
- Warfarin: Vitamin K + 4-factor PCC (Kcentra)
- Dabigatran: Idarucizumab (Praxbind)
- Factor Xa inhibitors: Andexanet alfa
- tPA-related: Cryoprecipitate 10U IV (target fibrinogen ≥150 mg/dL), FFP
- BP control: Target SBP <140 mmHg (some guidelines 130-150)
- Labetalol 10 mg IV bolus (repeat q10-20 min, max 300 mg) or nicardipine infusion 5-15 mg/h
- ICP management: HOB 30°, osmotherapy (mannitol/hypertonic saline)
- Surgical hematoma evacuation: Considered for cerebellar hemorrhage >3 cm, or herniation; less benefit for supratentorial unless accessible
Subarachnoid Hemorrhage (SAH - Aneurysmal)
- SBP <160 mmHg (AHA/ASA) until aneurysm secured
- Secure the aneurysm: Endovascular coiling preferred over surgical clipping when both are feasible (early, within 72 hours)
- Nimodipine 60 mg q4h for 21 days (prevents vasospasm / cerebral ischemia)
- Monitor for vasospasm: TCD, CTA angiography; treat with triple-H therapy or endovascular intervention
Summary Algorithm
STROKE SUSPECTED
|
CT Head (non-contrast)
|
--------+--------
| |
ISCHEMIC HEMORRHAGIC
| |
Eligible for Reverse anticoagulation
tPA? YES -----> IV Alteplase or TNK BP control, neurosurgery consult
(0-4.5h)
|
LVO on CTA?
YES ------> EVT (Thrombectomy)
|
Antiplatelet (aspirin ± clopidogrel)
|
Secondary prevention
(statin, antihypertensives, anticoagulation if AF)
Key 2026 Updates (vs. 2018/2019):
- Tenecteplase now equal to alteplase within 4.5 hours
- Extended time window for IVT up to 9 hours with imaging guidance
- Broader EVT eligibility - extended to 24 hours with perfusion imaging
- DAPT for 21 days firmly established for minor stroke/TIA
- Pediatric stroke addressed as a dedicated section
- Simplified contraindications to thrombolysis
- Rosen's Emergency Medicine: Concepts and Clinical Practice (9780323757898), Ch. 87
- 2026 AHA/ASA Guideline for Acute Ischemic Stroke - Prabhakaran et al., Stroke 2026
- NIH StatPearls - Ischemic Stroke
This is a shared conversation. Sign in to Orris to start your own chat.